French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. from the National Reference and the Competence centers for rare diseases and the Société de Pneumologie de Langue Française;Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique. Élaborées par le centre national de référence et les centres de compétence pour les maladies pulmonaires rares sous l'égide de la Société de pneumologie de langue française

Revue des Maladies Respiratoires

Volumn 30, Issue 10, 2013, Pages 879-902

  Cottin, V ^a   Crestani, B ^b   Valeyre, D ^c   Wallaert, B ^d   Cadranel, J ^e   Dalphin, J C ^f   Delaval, P ^g   Israel Biet, D ^h   Kessler, R ⁱ   Reynaud Gaubert, M ^j   Cordier, J F ^a   Aguilaniu, B ^k   Bouquillon, B ^l   Carre P ^m   Danel, C ^b   Faivre, J B ^d   Ferreti, G ⁿ   Just, N ^o   Kouzan, S ^p   Lebargy, F ^q   Marchand Adam, S ^r   Philippe, B ^s   Prevot G ^t   Stach, B ^u   Thivolet Bejui F ^v   more..

^a UNIVERSITÉ DE LYON   (France)

^b BICHAT HOSPITAL   (France)

^c AVICENNE HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e HÔPITAL TENON   (France)

^f UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^g PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^h Section of Radiology   (France)

ⁱ HÔPITAL DE HAUTEPIERRE   (France)

^j HÔPITAL NORD   (France)

^k Clinique du Mail   (France)

^l Opened Mind Health   (France)

^m Hôpital Bretonneau ^*  (France)

ⁿ HÔPITAL MICHALLON   (France)

^o CENTRE HOSPITALIER DE ROUBAIX   (France)

^p Centre Hospitalier Intercommunal Sud Léman   (France)

^q HÔPITAL MAISON BLANCHE   (France)

^r CHU BRETONNEAU   (France)

^s CENTRE HOSPITALIER RENÉ DUBOS   (France)

^t SERVICE DE PNEUMOLOGIE   (France)

^u Cabinet medical   (France)

^v LOUIS PRADEL HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; FIBROSING ALVEOLITIS; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE;

ACETYLCYSTEINE; ADRENAL CORTEX HORMONES; ANTIBODIES; ANTICOAGULANTS; COLCHICINE; DIAGNOSTIC TECHNIQUES, RESPIRATORY SYSTEM; FRANCE; GENETIC TESTING; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERDISCIPLINARY COMMUNICATION; PATIENT CARE TEAM; VACCINATION;

EID: 84896694734     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2013.09.007     Document Type: Article

References (141)

1. Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence andprevalence of idiopathic pulmonary fibrosis: review of theliterature. Eur Respir Rev 2012;21:355-61.
2. Raghu G, Collard HR, Egan JJ, et al. An OfficialATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management. AmJ Respir Crit Care Med 2011;183:788-824.
3. Célaboration de recommandations de bonne pratique.Méthode. « Recommandations pour la pratique clinique »http://www.has-sante. fr/portail/upload/docs/application/df 2011-01/guide methodologique recommandations pourla pratique clinique.pdf Accès 1er juin 2012.
4. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mor-tality of idiopathic pulmonary fibrosis and sarcoidosis in theUK. Thorax 2006;61:980-5.
5. Scott J, Johnston I, Britton J. What causes cryptogenicfibrosing alveolitis? A case-control study of environmentalexposure to dust. Br Med J 1990;301:1015-7.
6. Mannino DM, Etzel RA, Parrish RG. Pulmonary fibrosis deaths inthe Unisted States, 1979-1991. An analysis of multiple-causemortality data. Am J Respir Crit Care Med 1996;153:1548-52.
7. Raghu G, Freudenberger TD, Yang S, et al. High prevalence ofabnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006;27:136-42.
8. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone,or no therapy on survival. Am J Respir Crit Care Med2000;161:1172-8.
9. King Jr TE, Tooze JA, Schwarz MI, et al. Predicting survivalin idiopathic pulmonary fibrosis: scoring system and survivalmodel. Am J Respir Crit Care Med 2001;164:1171-81.
10. Cottin V, Cordier JF. Velcro crackles: the key for earlydiagnosis of idiopathic pulmonary fibrosis? Eur Respir J2012;40:519-21.
11. American Thoracic Society/European Respiratory SocietyInternational Multidisciplinary Consensus. Classification ofthe Idiopathic Interstitial Pneumonias. Am J Respir Crit CareMed 2002;165:277-304.
12. Park JH, Kim DS, Park IN, et al. Prognosis of fibroticinterstitial pneumonia: idiopathic versus collagen vascu-lar disease-related subtypes. Am J Respir Crit Care Med2007;175:705-11.
13. Cottin V. Interstitial lung disease: are we missingformes frustes of connective tissue disease? Eur RespirJ 2006;28:893-6.
14. Foulon G, Delaval P, Valeyre D, et al. ANCA-associatedlung fibrosis: analysis of 17 patients. Respir Med 2008;102:1392-8.
15. Meyer KC, Raghu G, Baughman RP, et al. An official Ameri-can Thoracic Society clinical practice guideline: the clinicalutility of bronchoalveolar lavage cellular analysis in inter-stitial lung disease. Am J Respir Crit Care Med 2012;185:1004-14.
16. Ohshimo S, Bonella F, Cui A, et al. Significance of bron-choalveolar lavage for the diagnosis of idiopathic pulmonaryfibrosis. Am J Respir Crit Care Med 2009;179:1043-7.
17. Bitterman PB, Rennard SI, Keogh BA, et al. Familial idiopathicpulmonary fibrosis. Evidence of lung inflammation in unaffec-ted family members. N Engl J Med 1986;314:1343-7.
18. Marshall RP, Puddicombe A, Cookson WO, et al. Adult familialcryptogenic fibrosing alveolitis in the United Kingdom. Thorax2000;55:143-6.
19. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence ofsporadic and familial idiopathic pulmonary fibrosis: evidenceof founder effect among multiplex families in Finland. Thorax2002;57:338-42.
20. Lee HL, Ryu JH, Wittmer MH, et al. Familial idiopathicpulmonary fibrosis: clinical features and outcome. Chest2005;127:2034-41.
21. Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologicfeatures of familial interstitial pneumonia. Am J Respir CritCare Med 2005;172:1146-52.
22. Rosas IO, Ren P, Avila NA, et al. Early interstitial lung diseasein familial pulmonary fibrosis. Am J Respir Crit Care Med2007;176:698-705.
23. Musk AW, Zilko PJ, Manners P, et al. Genetic studies in familial fibrosing alveolitis. Possible linkage with immunoglobulinallotypes (Gm). Chest 1986;89:206-10.
24. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutationsin families with idiopathic pulmonary fibrosis. N Engl J Med2007;356:1317-26.
25. Young NS. Telomere biology and telomere diseases: implica-tions for practice and research. Hematology Am Soc HematolEduc Prog 2010;2010:30-5.
26. Nogee LM, Dunbar 3rd AE, Wert SE, et al. A mutation in thesurfactant protein C gene associated with familial interstitiallung disease. N Engl J Med 2001;344:573-9.
27. Thomas AQ, Lane K, Phillips 3rd J, et al. Heterozygosityfor a surfactant protein C gene mutation associated withusual interstitial pneumonitis and cellular nonspecific inter-stitial pneumonitis in one kindred. Am J Respir Crit Care Med2002;165:1322-8.
28. Crossno PF, Polosukhin VV, Blackwell TS, et al. Identificationof early interstitial lung disease in an individual with geneticvariations in ABCA3 and SFTPC. Chest 2010;137:969-73.
29. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal declinein forced vital capacity is associated with a poor out-come in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:830-6.
30. du Bois RM, Weycker D, Albera C, et al. Forced vital capacityin patients with idiopathic pulmonary fibrosis: test propertiesand minimal clinically important difference. Am J Respir CritCare Med 2011;184:1382-9.
31. Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus abso-lute change in forced vital capacity in idiopathic pulmonaryfibrosis. Thorax 2012;67:407-11.
32. Wells AU. Forced vital capacity as a primary end point in idio-pathic pulmonary fibrosis treatment trials: making a silk pursefrom a sow's ear. Thorax 2013;68:309-10.
33. Cottin V, Capron F, Grenier P, et al. Pneumopathies inter-stitielles diffuses idiopathiques. Classification de Consen-sus International Multidisciplinaire de l'American ThoracicSociety et de l'European Respiratory Society, principales enti-tés anatomo-cliniques, et conduite du diagnostic. Rev MalRespir 2004;21:299-318.
34. Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access andsurvival in idiopathic pulmonary fibrosis: a cohort study. AmJ Respir Crit Care Med 2011;184:842-7.
35. Ley B, Collard HR, King Jr TE. Clinical course and predictionof survival in idiopathic pulmonary fibrosis. Am J Respir CritCare Med 2011;183:431-40.
36. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk testin idiopathic pulmonary fibrosis: test validation and minimalclinically important difference. Am J Respir Crit Care Med2011;183:1231-7.
37. du Bois RM, Weycker D, Albera C, et al. Ascertainment of indi-vidual risk of mortality for patients with idiopathic pulmonaryfibrosis. Am J Respir Crit Care Med 2011;184:459-66.
38. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensionalindex and staging system for idiopathic pulmonary fibrosis.Ann Intern Med 2012;156:684-91.
39. Demedts M, Behr J, Buhl R, et al. IFIGENIA: effects of N-acetylcysteine (NAC) on primary end points VC and DLco. EurRespir J 2004;24:668s.
40. Raghu G, Anstrom KJ, King Jr TE, et al. Prednisone, azathio-prine, and N-acetylcysteine for pulmonary fibrosis. N Engl JMed 2012;366:1968-77.
41. Nagai S, Kitaichi M, Hamada K, et al. Hospital-based his-torical cohort study of 234 histologically proven Japanesepatients with IPF. SarcoidosisVasc Diffuse Lung Dis 1999;16:209-14.
42. Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonaryfibrosis: predicting response to therapy and survival. Am JRespir Crit Care Med 1998;157:1063-72.
43. Winterbauer RH, Hammar SP, Hallman KO, et al. Diffuseinterstitial pneumonitis. Clinicopathologic correlations in 20 atients treated with prednisone/azathioprine. Am J Med1978;65:661-72.
44. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combinedwith prednisone in the treatment of idiopathic pulmonaryfibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991;144:291-6.
45. Johnson MA, Kwan S, Snell NJ, et al. Randomised controlledtrial comparing prednisolone alone with cyclophosphamideand low dose prednisolone in combination in cryptogenicfibrosing alveolitis. Thorax 1989;44:280-8.
46. Collard HR, Ryu JH, Douglas WW, et al. Combined corticoste-roid and cyclophosphamide therapy does not alter survival inidiopathic pulmonary fibrosis. Chest 2004;125:2169-74.
47. Pereira CA, Malheiros T, Coletta EM, et al. Survival inidiopathic pulmonary fibrosis-cytotoxic agents compared tocorticosteroids. Respir Med 2006;100:340-7.
48. Hope-Gill BD, Hilldrup S, Davies C, et al. A study of the coughreflex in idiopathic pulmonary fibrosis. Am J Respir Crit CareMed 2003;168:995-1000.
49. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapyfor idiopathic pulmonary fibrosis. Chest 2005;128:1475-82.
50. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlledrandomized trial of warfarin in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2012;186:88-95.
51. Fiorucci E, Lucantoni G, Paone G, et al. Colchicine, cyclophos-phamide and prednisone in the treatment of mild-moderateidiopathic pulmonary fibrosis: comparison of three currentlyavailable therapeutic regimens. Eur Rev Med Pharmacol Sci2008;12:105-11.
52. Antoniou KM, Nicholson AG, Dimadi M, et al. Long-termclinical effects of interferon gamma-1b and colchicinein idiopathic pulmonary fibrosis. Eur Respir J 2006;28:496-504.
53. Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versusprednisone in the treatment of idiopathic pulmonary fibrosis.A randomized prospective study. Members of the Lung StudyGroup. Am J Respir Crit Care Med 1998;158:220-5.
54. Grgic A, Lausberg H, Heinrich M, et al. Progression of fibro-sis in usual interstitial pneumonia: serial evaluation of thenative lung after single lung transplantation. Respiration2008;76:139-45.
55. Wahidi MM, Ravenel J, Palmer SM, et al. Progression of idio-pathic pulmonary fibrosis in native lungs after single lungtransplantation. Chest 2002;121:2072-6.
56. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlledtrial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-33.
57. King Jr TE, Albera C, Bradford WZ, et al. Effect of inter-feron gamma-1b on survival in patients with idiopathicpulmonary fibrosis (INSPIRE): a multicentre, randomised,placebo-controlled trial. Lancet 2009;374:222-8.
58. King Jr TE, Behr J, Brown KK, et al. BUILD-1: a randomizedplacebo- controlled trial of bosentan in idiopathic pulmonaryfibrosis. Am J Respir Crit Care Med 2008;177:75-81.
59. King Jr TE, Brown KK, Raghu G, et al. BUILD-3: a randomized,controlled trial of bosentan in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2011;184:92-9.
60. Raghu G, Million-Rousseau R, Morganti A, et al. Macitentan forthe treatment of idiopathic pulmonary fibrosis: the randomi-sed controlled MUSIC trial. Eur Respir J 2013 [Epub ahead ofprint, PMID: 23682110 (PubMed- as supplied by publisher)].
61. Raghu G, Behr JBKK, Egan J, et al. ARTEMIS-IPF: a placebo-controlled trial of ambrisentan in idiopathic pulmonaryfibrosis. Am J Respir Crit Care Med 2012;185:A3632.
62. Raghu G, Brown KK, Costabel U, et al. Treatment of idio-pathic pulmonary fibrosis with etanercept: an exploratory,placebo-controlled trial. Am J Respir Crit Care Med 2008;178:948-55.
63. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone inpatients with idiopathic pulmonary fibrosis (CAPACITY): tworandomised trials. Lancet 2011;377:1760-9.
64. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathicpulmonary fibrosis. Eur Respir J 2010;35:821-9.
65. Continuous or nocturnal oxygen therapy in hypoxemicchronic obstructive lung disease: a clinical, trial. Noctur-nal oxygen therapy trial group. Ann Intern Med 1980;93:391-8.
66. Long term domiciliary oxygen therapy in chronic hypoxic corpulmonale complicating chronic bronchitis and, emphysema.,Report of the Medical Research Council Working, Party. Lancet1981;1:681-6.
67. Holland AE, Hill CJ, Conron M, et al. Short term improvementin exercise capacity and symptoms following exercise trainingin interstitial lung disease. Thorax 2008;63:549-54.
68. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonaryrehabilitation in patients with idiopathic pulmonary fibrosis.Respirology 2008;13:394-9.
69. Ferreira A, Garvey C, Connors GL, et al. Pulmonary rehabili-tation in interstitial lung disease: benefits and predictors ofresponse. Chest 2009;135:442-7.
70. Holland AE, Hill CJ, Glaspole I, et al. Predictors of benefit fol-lowing pulmonary rehabilitation for interstitial lung disease.Respir Med 2012;106:429-35.
71. Kozu R, Senjyu H, Jenkins SC, et al. Differences in responseto pulmonary rehabilitation in idiopathic pulmonary fibro-sis and chronic obstructive pulmonary disease. Respiration2011;81:196-205.
72. Huppmann P, Sczepanski B, Boensch M, et al. Effects of in-patient pulmonary rehabilitation in patients with interstitiallung disease. Eur Respir J 2013;42:444-53.
73. Mason DP, Brizzio ME, Alster JM, et al. Lung transplan-tation for idiopathic pulmonary fibrosis. Ann Thorac Surg2007;84:1121-8.
74. Keating D, Levvey B, Kotsimbos T, et al. Lung transplantationin pulmonary fibrosis: challenging early outcomes counter-balanced by surprisingly good outcomes beyond 15 years.Transplant Proc 2009;41:289-91.
75. Thabut G, Mal H, Castier Y, et al. Survival benefit of lung trans-plantation for patients with idiopathic pulmonary fibrosis. JThorac Cardiovasc Surg 2003;126:469-75.
76. Orens JB, Estenne M, Arcasoy S, et al. International guidelinesfor the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council ofthe International Society for Heart and Lung Transplantation.J Heart Lung Transplant 2006;25:745-55.
77. Thabut G, Christie JD, Ravaud P, et al. Survival after bilateralversus single-lung transplantation for idiopathic pulmonaryfibrosis. Ann Intern Med 2009;151:767-74.
78. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbationsof idiopathic pulmonary fibrosis. Am J Respir Crit Care Med2007;176:636-43.
79. Raghu G. Idiopathic pulmonary fibrosis: increased survivalwith "gastroesophageal reflux therapy": fact or fallacy? AmJ Respir Crit Care Med 2011;184:1330-2.
80. Morawiec E, Tillie-Leblond I, Pansini V, et al. Exacerbationsof idiopathic pulmonary fibrosis treated with corticoste-roids and cyclophosphamide pulses. Eur Respir J 2011;38:1487-9.
81. Blivet S, Philit F, Sab JM, et al. Outcome of patients with idio-pathic pulmonary fibrosis admitted to the ICU for respiratoryfailure. Chest 2001;120:209-12.
82. Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopa-thic pulmonary fibrosis: frequency and clinical features. EurRespir J 2006;27:143-50.
83. Molina-Molina M, Badia JR, Marin-Arguedas A, et al. [Out-comes and clinical characteristics of patients with pulmonary fibrosis and respiratory failure admitted to an intensive careunit. A study of 20 cases]. Med Clin (Barc) 2003;121:63-7.
84. Saydain G, Islam A, Afessa B, et al. Outcome of patients withidiopathic pulmonary fibrosis admitted to the intensive careunit. Am J Respir Crit Care Med 2002;166:839-42.
85. Nava S, Rubini F. Lung and chest wall mechanics in ventilatedpatients with end stage idiopathic pulmonary fibrosis. Thorax1999;54:390-5.
86. Stern JB, Mal H, Groussard O, et al. Prognosis ofpatients with advanced idiopathic pulmonary fibrosis requi-ring mechanical ventilation for acute respiratory failure.Chest 2001;120:213-9.
87. Al-Hameed FM, Sharma S. Outcome of patients admitted tothe intensive care unit for acute exacerbation of idiopathicpulmonary fibrosis. Can Respir J 2004;11:117-22.
88. Fumeaux T, Rothmeier C, Jolliet P. Outcome of mechanicalventilation for acute respiratory failure in patients with pulmonary fibrosis. Intensive Care Med 2001;27:1868-74.
89. Mollica C, Paone G, Conti V, et al. Mechanical ventilation inpatients with end-stage idiopathic pulmonary fibrosis. Respi-ration 2010;79:209-15.
90. Ranga P, Moran JL. Outcomes of patients admitted to theintensive care unit with idiopathic pulmonary fibrosis. CritCare Resusc 2009;11:102-9.
91. Mallick S. Outcome of patients with idiopathic pulmonaryfibrosis (IPF) ventilated in intensive care unit. Respir Med2008;102:1355-9.
92. Yokoyama T, Kondoh Y, Taniguchi H, et al. Noninvasive venti-lation in acute exacerbation of idiopathic pulmonary fibrosis.Intern Med 2010;49:1509-14.
93. Nathan SD, Cottin V. Pulmonary hypertension in patientswith idiopathic pulmonary fibrosis. Eur Respir Mon2012;57:148-60.
94. Shorr AF, Wainright JL, Cors CS, et al. Pulmonary hypertensionin patients with pulmonary fibrosis awaiting lung transplant.Eur Respir J 2007;30:715-21.
95. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence andoutcomes of pulmonary arterial hypertension in advancedidiopathic pulmonary fibrosis. Chest 2006;129:746-52.
96. Judge EP, Fabre A, Adamali HI, et al. Acute exacerbationsand pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J 2012;40:93-100.
97. Nathan SD, Shlobin OA, Barnett SD, et al. Right ventricularsystolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. RespirMed 2008;102:1305-10.
98. Swanson KL, Utz JP, Krowka MJ. Doppler echocardiography-right heart catheterization relationships in patients withidiopathic pulmonary fibrosis and suspected pulmonary hyper-tension. Med Sci Monit 2008;14:CR177-82.
99. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiogra-phic assessment of pulmonary hypertension in patients withadvanced lung disease. Am J Respir Crit Care Med 2003;167:735-40.
100. Devaraj A, Wells AU, Meister MG, et al. The effect of diffusepulmonary fibrosis on the reliability of CT signs of pulmonaryhypertension. Radiology 2008;249:1042-9.
101. Leuchte HH, Baumgartner RA, Nounou ME, et al. Brainnatriuretic peptide is a prognostic parameter in chro-nic lung disease. Am J Respir Crit Care Med 2006;173:744-50.
102. Zisman DA, Karlamangla AS, Kawut SM, et al. Validation ofa method to screen for pulmonary hypertension in advancedidiopathic pulmonary fibrosis. Chest 2008;133:640-5.
103. Minai OA, Sahoo D, Chapman JT, et al. Vaso-active therapycan improve 6-min walk distance in patients with pulmonaryhypertension and fibrotic interstitial lung disease. Respir Med2008;102:1015-20.
104. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil fortreatment of lung fibrosis and pulmonary hypertension: a ran-domised controlled trial. Lancet 2002;360:895-900.
105. Madden BP, Allenby M, Loke TK, et al. A potential role forsildenafil in the management of pulmonary hypertension inpatients with parenchymal lung disease. Vascul Pharmacol2006;44:372-6.
106. Collard HR, Anstrom KJ, Schwarz MI, et al. Sildenafilimproves walk distance in idiopathic pulmonary fibrosis. Chest2007;131:897-9.
107. Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trialof sildenafil in advanced idiopathic pulmonary fibrosis. N EnglJ Med 2010;363:620-8.
108. Han MK, Bach DS, Hagan P, et al. Sildenafil preserves exercisecapacity in ipf patients with right ventricular dysfunc-tion. Chest 2013;143:1699-708, http://dx.doi.org/10.1378/chest.12-1594.
109. Hoeper MM, Halank M, Wilkens H, et al. Riociguat for inter-stitial lung disease and pulmonary hypertension: a pilot trial.Eur Respir J 2013;41:853-60.
110. Noth I, Zangan SM, Soares RV, et al. Prevalence of hiatal her-nia by blinded multidetector CT in patients with idiopathicpulmonary fibrosis. Eur Respir J 2012;39:344-51.
111. Tobin RW, Pope CE, Pellegrini CA, et al. Increased preva-lence of gastroesophageal reflux in patients with idiopathicpulmonary fibrosis. Am J Respir Crit Care Med 1998;158:1804-8.
112. Sweet MP, Patti MG, Leard LE, et al. Gastroesophageal refluxin patients with idiopathic pulmonary fibrosis referred forlung transplantation. J Thorac Cardiovasc Surg 2007;133:1078-84.
113. Tcherakian C, Cottin V, Brillet PY, et al. Progression of idiopa-thic pulmonary fibrosis: lessons from asymmetrical disease.Thorax 2011;66:226-31.
114. Lee JS, Collard HR, Raghu G, et al. Does chronic microas-piration cause idiopathic pulmonary fibrosis? Am J Med2010;123:304-11.
115. Linden PA, Gilbert RJ, Yeap BY, et al. Laparoscopicfundoplication in patients with end-stage lung disease awai-ting transplantation. J Thorac Cardiovasc Surg 2006;131:438-46.
116. Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal refluxtherapy is associated with longer survival in patients withidiopathic pulmonary fibrosis. Am J Respir Crit Care Med2011;184:1390-4.
117. Raghu G, Meyer KC. Silent gastro-oesophageal reflux andmicroaspiration in IPF: mounting evidence for anti-reflux therapy? Eur Respir J 2012;39:242-5.
118. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am JGastroenterol 2005;100:190-200.
119. Cottin V, Cordier JF. Combined pulmonary fibrosis and emphy-sema: an experimental and clinically relevant phenotype. AmJ Respir Crit Care Med 2005;172:1605 [author reply -6].
120. Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathicpulmonary fibrosis and emphysema: decreased survival asso-ciated with severe pulmonary arterial hypertension. Chest2009;136:10-5.
121. Cottin V, Le Pavec J, Prevot G, et al. Pulmonary hypertensionin patients with combined pulmonary fibrosis and emphysemasyndrome. Eur Respir J 2010;35:105-11.
122. Akagi T, Matsumoto T, Harada T, et al. Coexistent emphysemadelays the decrease of vital capacity in idiopathic pulmonaryfibrosis. Respir Med 2009;103:1209-15.
123. Schmidt SL, Nambiar AM, Tayob N, et al. Pulmonary func-tion measures predict mortality differently in IPF versuscombined pulmonary fibrosis and emphysema. Eur Respir J2011;38:176-83.
124. Clark M, Cooper B, Singh S, et al. A survey of nocturnalhypoxaemia and health related quality of life in patients withcryptogenic fibrosing alveolitis. Thorax 2001;56:482-6.
125. Aydogdu M, Ciftci B, Firat Guven S, et al. [Assessment ofsleep with polysomnography in patients with interstitial lungdisease]. Tuberk Toraks 2006;54:213-21.
126. Mermigkis C, Chapman J, Golish J, et al. Sleep-related brea-thing disorders in patients with idiopathic pulmonary fibrosis.Lung 2007;185:173-8.
127. Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleepapnea is common in idiopathic pulmonary fibrosis. Chest2009;136:772-8.
128. Series F, Cormier Y, Lampron N, et al. Increasing the functionalresidual capacity may reverse obstructive sleep apnea. Sleep1988;11:349-53.
129. Heinzer RC, Stanchina ML, Malhotra A, et al. Lung volume andcontinuous positive airway pressure requirements in obstruc-tive sleep apnea. Am J Respir Crit Care Med 2005;172:114-7.
130. [Recommendations for clinical practice. Obstructive sleepapnea hypopnea syndrome in adults]. Rev Mal Respir2010;27:806-33.
131. Horton MR, Danoff SK, Lechtzin N. Thalidomide inhibits theintractable cough of idiopathic pulmonary fibrosis. Thorax2008;63:749.
132. Horton MR, Santopietro V, Mathew L, et al. Thalidomide forthe treatment of cough in idiopathic pulmonary fibrosis: arandomized trial. Ann Intern Med 2012;157:398-406.
133. Allen S, Raut S, Woollard J, et al. Low dose diamorphinereduces breathlessness without causing a fall in oxygen satu-ration in elderly patients with end-stage idiopathic pulmonaryfibrosis. Palliat Med 2005;19:128-30.
134. Morrison DA, Stovall JR. Increased exercise capacity inhypoxemic patients after long-term oxygen therapy. Chest1992;102:542-50.
135. Visca D, Montgomery A, de Lauretis A, et al. Ambulatoryoxygen in interstitial lung disease. Eur Respir J 2011;38:987-90.
136. Frank RC, Hicks S, Duck AM, et al. Ambulatory oxygen inidiopathic pulmonary fibrosis: of what benefit? Eur Respir J2012;40:269-70.
137. Hubbard R, Venn A, Lewis S, et al. Lung cancer and cryptoge-nic fibrosing alveolitis. A population-based cohort study. AmJ Respir Crit Care Med 2000;161:5-8.
138. Turner-Warwick ME, Burrows B, Johnson A. Cryptogenicfibrosing alveolitis: clinical features and their influence onsurvival. Thorax 1980;35:171-80.
139. Harris JM, Johnston ID, Rudd R, et al. Cryptogenic fibro-sing alveolitis and lung cancer: the BTS study. Thorax2010;65:70-6.
140. Ozawa Y, Suda T, Naito T, et al. Cumulative incidence ofand predictive factors for lung cancer in IPF. Respirology2009;14:723-8.
141. Fell CD. Idiopathic pulmonary fibrosis: phenotypes and comor-bidities. Clin Chest Med 2012;33:51-7.